Related Experiment Video
Updated: Jun 4, 2026

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Mupirocin: biosynthesis, special features and applications of an antibiotic from a gram-negative bacterium
Rachel Gurney1, Christopher M Thomas
1School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. Rsg893@bham.ac.uk
Abstract:
Mupirocin is a polyketide antibiotic produced by Pseudomonas fluorescens. The biosynthetic cluster encodes 6 type I polyketide synthase multifunctional proteins and 29 single function proteins. The biosynthetic pathway belongs to the trans-AT group in which acyltransferase activity is provided by a separate polypeptide rather than in-cis as found in the original type I polyketide synthases. Special features of this group are in-cis methyltransferase domains and a trans-acting HMG-CoA synthase-cassette which insert α- and β- methyl groups respectively while enoyl reductase domains are absent from the condensing modules. In addition, for the mupirocin system, there is no obvious loading mechanism for initiation of the polyketide chain and many aspects of the pathway remain to be elucidated. Mupirocin inhibits isoleucyl-tRNA synthetase and has been used since 1985 to help prevent infection by methicillin-resistant Staphylococcus aureus, particularly within hospitals. Resistance to mupirocin was first detected in 1987 and high-level resistance in S. aureus is due to a plasmid-encoded second isoleucyl-tRNA synthetase, a more eukaryotic-like enzyme. Recent analysis of the biosynthetic pathway for thiomarinols from marine bacteria opens up possibilities to modify mupirocin so as to overcome this resistance.
Insights
Mupirocin, an antibiotic targeting isoleucyl-tRNA synthetase, faces resistance due to a secondary enzyme. Modifying its biosynthetic pathway, inspired by marine bacteria, may overcome this challenge.
Area of Science:
- Microbiology
- Biochemistry
- Genetics
Background:
- Mupirocin is a polyketide antibiotic from Pseudomonas fluorescens.
- Its biosynthesis involves a trans-AT type I polyketide synthase system with unique features like separate acyltransferase polypeptides and absent enoyl reductase domains.
- Mupirocin inhibits isoleucyl-tRNA synthetase and is crucial for combating methicillin-resistant Staphylococcus aureus (MRSA).
Purpose of the Study:
- To elucidate the complex biosynthetic pathway of mupirocin.
- To understand the mechanisms of mupirocin resistance in Staphylococcus aureus.
- To explore potential modifications of mupirocin to overcome existing resistance.
Main Methods:
- Analysis of the mupirocin biosynthetic gene cluster.
- Characterization of type I polyketide synthase components and their activities.
- Investigation of the genetic basis for mupirocin resistance in Staphylococcus aureus.
Main Results:
- The mupirocin biosynthetic pathway exhibits characteristics of the trans-AT group, including separate acyltransferase polypeptides and specific methyltransferase domains.
- High-level mupirocin resistance in S. aureus is linked to a plasmid-encoded, eukaryotic-like isoleucyl-tRNA synthetase.
- The absence of obvious loading mechanisms and enoyl reductase domains presents unique challenges in pathway elucidation.
Conclusions:
- The unique biosynthetic pathway of mupirocin offers insights into polyketide synthesis.
- Understanding mupirocin resistance mechanisms is critical for effective clinical use.
- Investigating related pathways, such as that of thiomarinols, presents opportunities for developing next-generation mupirocin analogs to combat resistance.
More Related Videos
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Biosynthesis in Bacteria
Inhibitors of Bacterial Protein Synthesis
Gene Regulation in Microbial Communities: Quorum Sensing

